Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study - Archive ouverte HAL Access content directly
Journal Articles British Journal of Haematology Year : 2017

Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study

(1) , (2) , (3) , (4) , , (5) , (6) , , (7) , (8) , , (9) , (10) , , (11) , (12) , (13) , (14) , , (15) , (16, 17) , (18) , (19) , (20)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Helder Fernandes
Yves Bertrand
  • Function : Author
  • PersonId : 938340
Fabrice Monpoux
  • Function : Author
Alain Fisher
  • Function : Author
Fanny Fouissac
  • Function : Author
Philippe Vic
  • Function : Author
Yves Perel
  • Function : Author

Dates and versions

hal-02413031 , version 1 (16-12-2019)

Identifiers

Cite

Stephane Ducassou, Guy Leverger, Helder Fernandes, Hervé Chambost, Yves Bertrand, et al.. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. British Journal of Haematology, 2017, 177 (5), pp.751-758. ⟨10.1111/bjh.14627⟩. ⟨hal-02413031⟩
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More